MedPath

Tagged News

Bluejay Diagnostics Raises $4.5 Million to Advance FDA Approval for Rapid Sepsis Diagnostic Test

FDA Approval
  • Bluejay Diagnostics completed a $4.5 million private placement to fund FDA approval activities and clinical studies for its sepsis diagnostic technology.
  • The company's Symphony System features an IL-6 Test designed to deliver sepsis triage results in approximately 20 minutes from sample to result.
  • Proceeds will support research and development activities for the near-patient testing system aimed at improving critical care decision-making.
  • The funding represents a strategic investment in rapid diagnostic technology that could enhance sepsis treatment outcomes through earlier detection.

Arcadia Medicine Receives FDA Approval for Clinical Trials of Safer MDMA Formulation AM-1002

FDA Approval
  • Arcadia Medicine, a San Francisco-based biotech company backed by Sam Altman, has received FDA approval to begin Phase 1 clinical trials of AM-1002, a reformulated version of MDMA designed to reduce neurotoxicity and cardiovascular side effects.
  • The company plans to initiate clinical trials for Generalized Anxiety Disorder treatment, with early-stage results expected within a year and eventual goals of at-home prescription use.
  • AM-1002 belongs to the empathogen class of psychoactive drugs and has been engineered to maintain therapeutic effects while minimizing traditional MDMA risks including overheating, high heart rate, and dehydration.
  • The company has secured $10 million in investment from notable tech industry figures including OpenAI's Sam Altman, Coinbase co-founder Fred Ehrsam, and Figma founder Dylan Field.

FDA Approves Restart of NobleStitch Clinical Trial for Device-Free PFO Closure

FDA Approval
  • The FDA has granted approval for Nobles Medical Technology II to restart its pivotal NobleStitch clinical trial, evaluating the first device-free, suture-mediated system for patent foramen ovale closure to reduce recurrent cryptogenic stroke.
  • The trial was proactively paused by CEO Dr. Anthony Nobles to enhance safety standards and protocol robustness, with patient enrollment expected to resume in Q4 2025.
  • The NobleStitch EL system uses proprietary percutaneous suturing to close intracardiac defects without permanent implants, potentially reducing complications from conventional metal mesh occluders including nickel hypersensitivity.
  • Rush University Medical Center has been added as a new clinical site under Dr. Josh Murphy's direction, with the company planning to submit a Pre-Market Approval application upon study completion.

FDA Launches Fast-Track Review Program for U.S.-Made Generic Drugs to Strengthen Supply Chain Resilience

FDA Approval
  • The FDA has introduced a new fast-track review program for domestically manufactured generic drugs to reduce reliance on overseas suppliers and address drug shortages.
  • The initiative offers accelerated review timelines as regulatory and commercial incentives for companies to expand U.S. manufacturing capacity.
  • Industry experts view the program as addressing supply chain vulnerabilities while supporting national policy goals of reshoring essential medicines.
  • The move is part of broader efforts to enhance access to affordable medications while maintaining quality standards.

SS Innovations Pivots to 510(k) Pathway for SSi Mantra Surgical Robot FDA Approval

FDA Approval
  • SS Innovations successfully completed a human factors validation study for its SSi Mantra surgical robotic system at Johns Hopkins Hospital in September 2025, meeting FDA requirements for usability and patient safety.
  • The company switched from a de novo request to the 510(k) regulatory pathway to potentially save time and costs, with submission planned for Q4 2025.
  • Based on standard FDA review timelines, the company expects potential clearance in the first half of 2026, which would enable market entry to compete with Intuitive Surgical.
  • The SSi Mantra system has demonstrated clinical success with 125 installations across six countries and over 6,000 surgical procedures performed to date.

ZOLL Zenix Monitor/Defibrillator Receives FDA Approval for Advanced Emergency Care

FDA Approval
  • ZOLL's Zenix monitor/defibrillator has received FDA premarket approval, marking the company's most clinically advanced emergency care device for EMS and hospital settings.
  • The device features innovative Real BVM Help and Real CPR Help technology that provides real-time clinical feedback to improve ventilation quality and CPR delivery.
  • Zenix combines intuitive touchscreen design with powerful functionality, allowing virtually all device functions to be accessible with three screen-touches or less.
  • The groundbreaking device is now available to customers in the U.S. and Canada, extending ZOLL's leadership in professional monitor/defibrillator technology.

FDA Authorizes First Spectacle Lens to Slow Myopia Progression in Children

FDA Approval
  • EssilorLuxottica received FDA market authorization for Essilor Stellest lenses, marking the first spectacle lens clinically proven to slow myopia progression in children aged 6-12 years.
  • Clinical trial data demonstrated a 71% reduction in myopia progression and 53% reduction in axial length elongation compared to single-vision control lenses over two years.
  • The authorization addresses a growing public health concern, as myopia affects 40% of the US population and is projected to impact half the world's population by 2050.
  • The lenses offer a lower-risk alternative to contact lenses for pediatric myopia management, with no serious adverse events reported in clinical trials.

Assessment of DOT Spectacles in Chinese Children

NCT05562622Active, Not RecruitingNot Applicable
SightGlass Vision, Inc.
Posted 2/5/2023

FDA Removes REMS Program for Vandetanib in Medullary Thyroid Cancer After Decade of Safe Use

FDA Approval
  • The FDA has removed the Risk Evaluation and Mitigation Strategies (REMS) program for vandetanib (Caprelsa) after more than a decade of postmarketing oversight showed no cases of Torsades de pointes or unexplained sudden deaths.
  • Vandetanib, approved in 2011 for metastatic or unresectable medullary thyroid cancer, originally required REMS due to QT prolongation risks and potentially fatal arrhythmias.
  • A 2021 retrospective study of 76 patients demonstrated median progression-free survival of 22.7 months overall, with long-term users achieving 73.2 months median PFS.
  • Cancer specialists now have adequate knowledge to manage heart rhythm-related risks, making formal REMS requirements unnecessary according to FDA officials.

An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer

NCT00410761CompletedPhase 3
Genzyme, a Sanofi Company
Posted 11/23/2006

Sequana Medical Advances US Commercialization of alfapump System with CMS Reimbursement Approval

FDA Approval
  • Sequana Medical has secured CMS approval for New Technology Add-on Payment (NTAP) reimbursement of up to $21,450 for the alfapump system, effective October 1, 2025.
  • The company is on track to complete at least 70 US commercial alfapump implants across eight hospitals during its "Soft Launch" phase through Q1 2026.
  • Following FDA approval in December 2024, Sequana has established a dedicated US commercial team and completed alfapump training at seven hospitals.
  • The alfapump system demonstrated effective ascites control and improved quality of life in the POSEIDON study, with published results showing higher overall survival compared to standard care.

St. Louis Children's Hospital Begins Administering FDA-Approved Gene Therapy Lyfgenia for Sickle Cell Disease

FDA Approval
  • St. Louis Children's Hospital is now administering Lyfgenia, an FDA-approved gene therapy developed by Bluebird Bio for treating sickle cell anemia patients.
  • The therapy involves extracting patient stem cells, genetically modifying them with a healthy hemoglobin gene, and reinfusing them after chemotherapy treatment.
  • Nearly 100,000 Americans suffer from sickle cell anemia, with the disease affecting 1 in every 265 African American births and reducing average life expectancy to approximately 40 years.
  • The treatment offers hope for patients like 20-year-old Martin Mwita Jr., who has endured decades of blood exchanges and pain crises associated with the genetic disorder.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.